NRI Wealth Management LC Makes New $149,000 Investment in Cryoport, Inc. (NASDAQ:CYRX)

NRI Wealth Management LC purchased a new stake in shares of Cryoport, Inc. (NASDAQ:CYRX) in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 19,131 shares of the company’s stock, valued at approximately $149,000. Cryoport makes up approximately 0.1% of NRI Wealth Management LC’s portfolio, making the stock its 25th biggest position.

Several other large investors have also recently modified their holdings of the stock. Quest Partners LLC grew its position in Cryoport by 1,083,000.0% during the 2nd quarter. Quest Partners LLC now owns 10,831 shares of the company’s stock valued at $75,000 after purchasing an additional 10,830 shares during the last quarter. Dynamic Technology Lab Private Ltd bought a new position in shares of Cryoport in the third quarter worth approximately $82,000. Hsbc Holdings PLC purchased a new stake in shares of Cryoport during the second quarter valued at approximately $92,000. Intech Investment Management LLC purchased a new stake in shares of Cryoport during the third quarter valued at approximately $105,000. Finally, The Manufacturers Life Insurance Company increased its position in shares of Cryoport by 9.5% during the second quarter. The Manufacturers Life Insurance Company now owns 17,683 shares of the company’s stock valued at $122,000 after acquiring an additional 1,534 shares in the last quarter. Hedge funds and other institutional investors own 92.90% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts recently issued reports on CYRX shares. Roth Mkm lowered their price objective on Cryoport from $18.00 to $15.00 and set a “buy” rating on the stock in a research report on Friday, November 8th. Guggenheim initiated coverage on Cryoport in a report on Thursday, December 19th. They set a “buy” rating and a $11.00 price target on the stock. Finally, UBS Group lifted their price objective on Cryoport from $7.00 to $9.00 and gave the stock a “neutral” rating in a report on Friday, October 18th. Three investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $12.29.

Insider Buying and Selling at Cryoport

In other Cryoport news, Director Ramkumar Mandalam sold 7,369 shares of the company’s stock in a transaction that occurred on Monday, December 2nd. The shares were sold at an average price of $7.46, for a total transaction of $54,972.74. Following the completion of the sale, the director now directly owns 59,497 shares of the company’s stock, valued at approximately $443,847.62. This represents a 11.02 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Jerrell Shelton sold 50,000 shares of Cryoport stock in a transaction on Thursday, November 21st. The stock was sold at an average price of $6.51, for a total transaction of $325,500.00. Following the transaction, the chief executive officer now owns 731,897 shares in the company, valued at $4,764,649.47. This represents a 6.39 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 109,869 shares of company stock valued at $735,673. 10.10% of the stock is owned by company insiders.

Cryoport Price Performance

NASDAQ CYRX opened at $7.98 on Friday. The stock has a market capitalization of $394.46 million, a price-to-earnings ratio of -2.36 and a beta of 1.62. Cryoport, Inc. has a 1-year low of $5.32 and a 1-year high of $20.10. The company has a debt-to-equity ratio of 0.48, a current ratio of 5.70 and a quick ratio of 5.32. The business’s fifty day moving average price is $7.51 and its 200-day moving average price is $7.85.

Cryoport Company Profile

Cryoport, Inc provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services.